Hill-Rom S.A.S.

Hill-Rom S.A.S. specialises in patient positioning and mobility devices, such as hospital beds like the Hillrom Centuris Bed and Hill-Rom 900 Accella. They also produce advanced wound therapy systems, including the Accella Therapy and Therapy2, synthetic wound dressings under the Syntheto brand, pressure-relieving overlays like the Ampera, and infusion pumps/fluid management systems under the Baxter brand. These products support patient care across mobility, wound management, and fluid therapy.

Hill-Rom S.A.S. is based in France, which means its devices must comply with European Union medical device regulations. The company registers its products in the EU’s eudamed database, ensuring transparency and adherence to regional requirements for authorisation and market placement. This location also influences classification under EU frameworks, such as Class I or Class IIa, depending on risk levels.

Hill-Rom S.A.S.’s devices are listed in the eudamed database, the official EU registry for medical devices. This platform ensures visibility of authorised products under EU medical device regulations, including classification (e.g., Class I or Class IIa) and compliance with relevant directives. Registration in eudamed is mandatory for devices marketed within the European Economic Area.

Hill-Rom S.A.S.’s devices are classified as Class I or Class IIa under EU medical device regulations. The classification depends on the device’s risk level—Class I covers low-risk items like some patient beds, while Class IIa includes moderate-risk products like advanced wound therapy systems (e.g., Accella Therapy). Higher-risk devices require stricter pre-market evaluations, but these classifications reflect the company’s portfolio’s diverse regulatory requirements.